Canadian Sec - Delayed Quote CAD

Revive Therapeutics Ltd. (RVV.CN)

Compare
0.0050 0.0000 (0.00%)
At close: January 6 at 2:07:23 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for RVV.CN

Recent News: RVV.CN

View More
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
GlobeNewswire 1 hour ago
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
GlobeNewswire last month
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
GlobeNewswire 3 months ago
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
GlobeNewswire 4 months ago
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
GlobeNewswire 6 months ago
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
GlobeNewswire 6 months ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
GlobeNewswire 8 months ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
GlobeNewswire 8 months ago
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
GlobeNewswire 9 months ago
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
GlobeNewswire 9 months ago
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
GlobeNewswire 9 months ago
View More

Related Tickers

TRIP.CN Red Light Holland Corp.
0.0450
+12.50%
 
PHRX.CN Pharmadrug Inc.
0.0150
0.00%
 
MYCO.CN Mydecine Innovations Group Inc.
0.0100
+100.00%
 
PWR.CN Captiva Verde Wellness Corp.
0.0350
-12.50%
 
LMLLF Pharmadrug Inc.
0.0107
0.00%
 
AION.CN Aion Therapeutic Inc.
0.0100
0.00%
 
VENI.CN Vencanna Ventures Inc.
0.0100
-33.33%
 
FFNT.CN 4Front Ventures Corp.
0.0200
-20.00%
 
OPTI.CN Optimi Health Corp.
0.2100
-8.70%
 
BCBC.CN The BC Bud Corporation
0.0800
0.00%